Novocure lanceert website over klinisch onderzoek
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, een bedrijf voor oncologie in de commerciële fase, heeft vandaag de lancering van zijn nieuwe website met informatie over klinische proeven gelanceerd, www.novocuretrials.com. De website is bedoeld als bron voor patiënten met een solide tumor en hun familieleden die informatie zoeken over klinische tests met Tumor Treating Fields (TTFields). De website biedt basisinformatie over TTFields, de ontwikkeling van lopende en geplande onderzoeken die door het bedrijf worden gesponsord, de doelgroep van deelnemers aan onderzoeken en de locaties van onderzoek. De website is beschikbaar in negen talen.
“Veel kankerpatiënten zoeken nooit naar klinisch onderzoeken en blijven in het ongewisse over experimentele behandelmogelijkheden”, zei Uri Weinberg, vicevoorzitter voor onderzoek en ontwikkeling. “We geloven dat deze website een belangrijk hulpmiddel voor patiënten en hun familieleden zal zijn doordat de website hun toegang geeft tot informatie over onze groeiende pijplijn van onderzoeken en informatie over onderzoekscentra en deelname aan innovatieve onderzoeken.”
Novocure Launches Clinical Trial Website at www.novocuretrials.com
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure, a commercial stage oncology company, announced today the launch of its new clinical trial website at www.novocuretrials.com. The website is intended to serve as a resource for patients suffering from solid tumor cancers and their families who seek information regarding clinical trials testing Tumor Treating Fields (TTFields). The website provides basic information about TTFields, the design of ongoing and planned company-sponsored trials, the target population for each trial, and trial locations. The website is available in nine languages.
“Many cancer patients do not seek out clinical trials and remain unaware of experimental treatment options,” said Uri Weinberg, MD, PhD, Novocure’s Vice President for Research and Development. “We believe that this new website will be an important tool for patients and their families by allowing them access to information about our growing clinical trial pipeline and information on how they can contact study centers to seek participation in these innovative studies.”
The website, located at www.novocuretrials.com, currently provides information on the following four ongoing trials.
- PANOVA: A Phase 2 study of TTFields combined with chemotherapy for newly-diagnosed pancreatic cancer
- INNOVATE: A Phase 2 study of TTFields combined with chemotherapy for recurrent ovarian cancer
- STELLAR: A Phase 2 study of TTFields combined with chemotherapy for mesothelioma
- COMET: A Phase 2 study of TTFields following local therapy for 1-5 brain metastasis from non-small-cell-lung cancer
About Tumor Treating Fields Therapy
Tumor Treating Fields (TTFields) therapy is delivered by a portable, non-invasive medical device designed for continuous use by patients.
In vitro and in vivo studies have shown that TTFields therapy slows and reverses tumor growth by inhibiting mitosis, the process by which cells divide and replicate. TTFields therapy creates low intensity, alternating electric fields within a tumor that exert physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death. TTFields therapy is not approved for the treatment of pancreatic cancer, ovarian cancer, mesothelioma or brain metastasis from non-small-cell-lung cancer. The safety and effectiveness of TTFields therapy in these indications has not been established.
Approved Indication
Optune is intended for the treatment of patients with recurrent GBM who have progressed after surgery, radiotherapy and temozolomide treatment for their primary disease. The treatment is intended for adult patients, 18 years of age or older, and should be started more than 4 weeks after the latest surgery, radiation therapy or chemotherapy.
Optune is intended for the treatment of patients with newly diagnosed GBM, after surgery and radiotherapy with adjuvant temozolomide, concomitant to maintenance temozolomide. The treatment is intended for adult patients, 18 years of age or older, and should be started more than 4 weeks after surgery and radiation therapy with adjuvant temozolomide. Treatment may be given together with maintenance temozolomide and after maintenance temozolomide is stopped.
About Novocure
Novocure is a private Jersey Isle oncology company pioneering a novel therapy for solid tumors called TTFields. Novocure’s US operations are based in Portsmouth, NH and New York, NY. Additionally, the company has offices in Switzerland and Japan and a research center in Haifa, Israel. For additional information about the company, please visit
www.novocure.com or follow us at www.twitter.com/novocure.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150709005342/en/
Contacts
Media and Investors:
Novocure
Ashley Cordova,
212-767-7558
acordova@novocure.com